Medical Oncology

Immune-related adverse events

Questions discussed in this category

What infections should we rule out in patients who develop diarrhea on immunotherapy?

Chemotherapy is associated with acquiring C diff colitis. Does immunotherapy share that same risk and necessitate ruling out infection prior to anti-d...

1 Answer available

How do you prescribe a steroid taper for radiation and checkpoint inhibitor related pneumonitis?

I've seen a handful of fatal radiation pneumonitis associated with rapid steroid tapers by the non-treating physicians. How do you recommend prescribi...

2 Answers available

What are your next steps for managing biopsy-proven interstitial nephritis from checkpoint inhibitors in patients who do not have a response to prednisone?

3 Answers available

How do you manage immunotherapy-induced myasthenia gravis?

2 Answers available

Is it safe to treat checkpoint inhibitor-induced arthritis with methotrexate or biologics?

1 Answer available

What is your surveillance approach for outpatient monitoring of ICI myocarditis?

(i.e. frequency of serial BNP, troponin, cMRI)

2 Answers available

When would you consider tapering glucocorticoids in a patient with ICI-associated myocarditis?

2 Answers available

What scenario would prophylactic Tocilizumab be considered to prevent Ipilimumab+Nivolumab (immunotherapy) induced toxicity in malignant melanoma?

1 Answer available

When do you perform a kidney biopsy in a patient with AKI that is thought to be related to an immune checkpoint inhibitor?

Do you wait to monitor response to empiric corticosteroids before pursuing a kidney biopsy?

2 Answers available

Do you recommend retreatment with an immune checkpoint inhibitor in a patient with a history of immune checkpoint inhibitor-related AKI that resolved with holding the immune checkpoint inhibitor and a glucocorticoid taper?

3 Answers available

What is the appropriate management of severe myalgia during atezolizumab infusion?

1 Answer available

Are there any risk factors for IO induced rhabdomyolysis and how do you approach and manage it?

2 Answers available

Would you give checkpoint inhibitor therapy to a cancer patient with known dermatomyositis given the association of checkpoint inhibitor associated myocarditis, myasthenia gravis, and myositis?

6 Answers available

Do you initiate management of new onset diabetes in a patient on immunotherapy or refer immediately to endocrinology given the risk of rapid worsening?

1 Answer available

Are there known biomarkers predictive of IRAEs?

3 Answers available

How do you discern whether elevated liver enzymes are from immunotherapy versus chemotherapy when a patient is on combination chemo/immunotherapy?

2 Answers available

Is IL-6 inhibition an option in patients who are going to be rechallenged with checkpoint inhibitors after previously developing ICI-mediated temporal arteritis?

Would the checkpoint inhibitor still work if blocking only that portion of the inflammatory cascade as opposed to more global blockade with steroids?

2 Answers available

How do you manage steroid-refractory immune checkpoint inhibitor induced pneumonitis?

4 Answers available

Can you continue checkpoint inhibitor therapy in the setting of severe cutaneous irAE while concurrently treating the cutaneous reaction?

2 Answers available

What is your preferred steroid sparing therapy in a patient experiencing a severe checkpoint inhibitor toxicity and not responding to high dose IV steroids?

2 Answers available

How would you approach the treatment of checkpoint-inhibitor-mediated temporal arteritis?

Is there role for IVIG? Would you alter the dose or time course of steroid therapy?

2 Answers available

How do you manage psoriatic arthritis in patients who are planning to start treatment with checkpoint inhibitors for underlying malignancy?

2 Answers available

What are your recommendations for a patient with metastatic non-mutated lung adenocarcinoma who previously had headaches responsive to prednisone but with negative temporal artery biopsy for GCA?

For medical oncologists, would you offer a PD-1/L1 inhibitor? For other subspecialties, how would you counsel the oncologist regarding the risk of usi...

1 Answer available

How would you treat a patient with metastatic renal cell cancer with Crohn's disease after failing available tyrosine kinase inhibitor therapies?

Is Crohn's diagnosis an absolute contraindication for immunotherapy?

3 Answers available

What features help distinguish thyroid myopathy from immune checkpoint inhibitor-associated myopathy?

1 Answer available

How would you approach evaluation and treatment of a patient on pembrolizumab therapy who presents with symmetric, proximal, upper extremity and lower extremity painful weakness without an elevated CK?

1 Answer available

When a patient with a preexisting rheumatic disease and on immunotherapy begins to flare, how do you decide if this is an underlying rheumatic disease activity versus an immunotherapy related adverse event?

How do you decide if it may be safe to continue immunotherapy?

1 Answer available

Is your approach to managing immune related adverse events altered at all in light of COVID-19?

2 Answers available

How do you approach further treatment of patients who develop grade 2-3 immune colitis from nivolumab/ipilimumab prior to completion of the 4 ipilimumab doses?

Do you re-challenge with nivolumab alone, change from nivo 1/ipi 3 to nivo 3/ipi 1 upon re-challenge, or stop immunotherapy altogether if grade 3?&nbs...

1 Answer available

Before re-challenging a patient with ICI after grade 1-2 pneumonitis, do you re-image to confirm resolution of pneumonitis?

1 Answer available

Would the need for infliximab/MTX/nonsteroidals to control initial irAE affect your decision to rechallenge these patients with ICI?

1 Answer available

How do you identify immunotherapy-related pneumonitis vs. radiation pneumonitis in a patient status post chemoradiation receiving consolidation immunotherapy?

Is IO related pneumonitis in the radiation field or more diffuse?

1 Answer available